Early effects of PP60v-src kinase activation on caveolae

1998 ◽  
Vol 71 (4) ◽  
pp. 524-535 ◽  
Author(s):  
Young-Gyu Ko ◽  
Pingsheng Liu ◽  
Ravindra K. Pathak ◽  
Leonard C. Craig ◽  
Richard G. W. Anderson
Keyword(s):  
Src Kinase ◽  
Kinase Activation ◽  
Early Effects

scholarly journals CXCL-12/Stromal Cell–Derived Factor-1α Transactivates HER2-neu in Breast Cancer Cells by a Novel Pathway Involving Src Kinase Activation

2005 ◽  
Vol 65 (15) ◽  
pp. 6493-6497 ◽  
Author(s):  
Neslihan Cabioglu ◽  
Justin Summy ◽  
Claudia Miller ◽  
Nila U. Parikh ◽  
Aysegul A. Sahin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Stromal Cell ◽  
Src Kinase ◽  
Kinase Activation ◽  
Stromal Cell Derived Factor

scholarly journals Destabilized Adhesion in the Gastric Proliferative Zone and c-Src Kinase Activation Mark the Development of Early Diffuse Gastric Cancer

2007 ◽  
Vol 67 (6) ◽  
pp. 2480-2489 ◽  
Author(s):  
Bostjan Humar ◽  
Ryuji Fukuzawa ◽  
Vanessa Blair ◽  
Anita Dunbier ◽  
Helen More ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Src Kinase ◽  
Diffuse Gastric Cancer ◽  
Kinase Activation ◽  
Proliferative Zone

Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

Blood ◽  
2006 ◽  
Vol 109 (2) ◽  
pp. 497-499 ◽  
Author(s):  
Alfonso Quintas-Cardama ◽  
Hagop Kantarjian ◽  
Dan Jones ◽  
Claude Nicaise ◽  
Susan O'Brien ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Kinase Inhibitors ◽  
Kinase Inhibitor ◽  
Philadelphia Chromosome ◽  
Src Kinase ◽  
Cytogenetic Response ◽  
Myelogenous Leukemia ◽  
Imatinib Resistance ◽  
Kinase Activation ◽  
Complete Hematologic Response

Abstract Developing strategies to counteract imatinib resistance constitutes a challenge in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high rates of hematologic and cytogenetic response. Src kinase activation has been linked to Bcr-Abl–mediated leukemogenesis and CML progression. In addition to binding Abl kinase with less stringent conformational requirements than imatinib, dasatinib is a potent Src kinase inhibitor. In the current study, we report on 23 patients with CML (19 of them in accelerated or blastic phases) treated with dasatinib after treatment failure with both imatinib and nilotinib. More than half (13; 57%) of 23 patients responded to dasatinib: 10 (43%) had a complete hematologic response (CHR), including 7 (30%) who had a cytogenetic response (2 complete, 4 partial, and 1 minor). These results suggest that dasatinib may be active in some patients after failure with both imatinib and nilotinib.

scholarly journals Time-Variant SRC Kinase Activation Determines Endothelial Permeability Response

2019 ◽  
Vol 26 (8) ◽  
pp. 1081-1094.e6 ◽  
Author(s):  
Jennifer E. Klomp ◽  
Mark Shaaya ◽  
Jacob Matsche ◽  
Rima Rebiai ◽  
Jesse S. Aaron ◽  
...  
Keyword(s):  
Src Kinase ◽  
Endothelial Permeability ◽  
Kinase Activation
Sign in / Sign up

Export Citation Format

Share Document